Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/JnVdEIaaAJ4.


NTLA Stock is one of the biggest gene editing stocks by market cap and the one likely to have the first in vivo gene editing therapy approved and marketed. That statement doesn't tell you squat about what you need to pay attention to as an investor. For any gene editing stock, you need to be focused on how close they are to bringing a lead candidate to market. That does two things. It proves the viability of their platform and it starts filling their coffers with cash. For Intellia, their lead candidate is going into a pivotal Phase 3 trial. Investors in Intellia stock need to hope there's no bad news because everything's been working well so far. If you're invested in $NTLA stock, you better watch this video otherwise the world's going to end. Is that convincing enough? And why are you reading this anyway? It's only meant to appease those dirty little AI algorithms that don't surface our videos because we don't run ads. (Kicks rocks.)

Ver todos los episodios